{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:30:51Z","timestamp":1785249051961,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.14283\/jpad.2023.27","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T10:10:31Z","timestamp":1678443031000},"page":"453-463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Outreach, Screening, and Randomization of APOE \u03b54 Carriers into an Alzheimer's Prevention Trial: A global Perspective from the API Generation Program"],"prefix":"10.1016","volume":"10","author":[{"given":"T.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Duff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. -E.","family":"Riviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.N.","family":"Tariot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Doak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Borowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lopez Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.C.","family":"Arratia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Scholten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Arbuckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ricart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Langbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.14283\/jpad.2023.27_bib1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/alz.12638","article-title":"2022 Alzheimer's disease facts and figures","volume":"18","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.14283\/jpad.2023.27_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer's disease and other dementias, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.14283\/jpad.2023.27_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/brain\/awz378","article-title":"Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age","volume":"143","author":"Betthauser","year":"2020","journal-title":"Brain"},{"issue":"8","key":"10.14283\/jpad.2023.27_bib4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.14283\/jpad.2023.27_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2217\/bmm.09.91","article-title":"Alzheimer's Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible","volume":"4","author":"Reiman","year":"2010","journal-title":"Biomarkers in Medicine"},{"issue":"3","key":"10.14283\/jpad.2023.27_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.0b013e318207b1b9","article-title":"Report of the task force on designing clinical trials in early (predementia) AD","volume":"76","author":"Aisen","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.14283\/jpad.2023.27_bib7","first-page":"68","article-title":"Registries and cohorts to accelerate early phase Alzheimer's trials. A report from the E.U.\/U.S. Clinical Trials in Alzheimer's Disease Task Force","volume":"3","author":"Aisen","year":"2016","journal-title":"J Prev Alz Dis"},{"issue":"2","key":"10.14283\/jpad.2023.27_bib8","first-page":"116","article-title":"Lessons Learned from Recent and Current Alzheimer's Prevention Trials","volume":"4","author":"Aisen","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"10.14283\/jpad.2023.27_bib9","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12737","article-title":"Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials","volume":"19","author":"Langbaum","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2023.27_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.trci.2019.02.005","article-title":"The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease","volume":"5","author":"Lopez","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.14283\/jpad.2023.27_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.trci.2019.09.013","article-title":"Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials","volume":"5","author":"Langlois","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"11","key":"10.14283\/jpad.2023.27_bib12","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/alz.12164","article-title":"Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease","volume":"16","author":"Wessels","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.14283\/jpad.2023.27_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","article-title":"Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b\/3 Clinical Trial","volume":"78","author":"Sperling","year":"2021","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.14283\/jpad.2023.27_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","article-title":"Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals","volume":"77","author":"Sperling","year":"2020","journal-title":"JAMA Neurol"},{"issue":"19","key":"10.14283\/jpad.2023.27_bib15","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"issue":"5123","key":"10.14283\/jpad.2023.27_bib16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"issue":"3","key":"10.14283\/jpad.2023.27_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1385\/JMN:23:3:157","article-title":"APOE genotype effects on Alzheimer's disease onset and epidemiology","volume":"23","author":"Ashford","year":"2004","journal-title":"J Mol Neurosci"},{"issue":"1","key":"10.14283\/jpad.2023.27_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ng0594-74","article-title":"Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease","volume":"7","author":"Van Duijn","year":"1994","journal-title":"Nat Genet"},{"issue":"S9","key":"10.14283\/jpad.2023.27_bib19","doi-asserted-by":"crossref","first-page":"e041139","DOI":"10.1002\/alz.041139","article-title":"The Generation program: Baseline characteristics of cognitively unimpaired APOE4 carriers recruited for Generation study 1 and Generation study 2","volume":"16","author":"Tariot","year":"2020","journal-title":"Alzheimer's & Dementia"},{"issue":"S9","key":"10.14283\/jpad.2023.27_bib20","doi-asserted-by":"crossref","first-page":"e041142","DOI":"10.1002\/alz.041142","article-title":"The API Generation program: Umibecestat treatment and discontinuation effects on hippocampal and whole brain volumes in the overall population and amyloid-negative APOE4 homozygotes","volume":"16","author":"Reiman","year":"2020","journal-title":"Alzheimer's & Dementia"},{"key":"10.14283\/jpad.2023.27_bib21","author":"McCaffrey"},{"issue":"4","key":"10.14283\/jpad.2023.27_bib22","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jalz.2018.12.007","article-title":"GeneMatch: a novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies","volume":"15","author":"Langbaum","year":"2019","journal-title":"Alzheimer's and Dementia"},{"issue":"4","key":"10.14283\/jpad.2023.27_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/cts.12759","article-title":"Approach to High Volume Enrollment in Clinical Research: Experiences from an All of Us Research Program Site","volume":"13","author":"Ilori","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.14283\/jpad.2023.27_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/WAD.0000000000000151","article-title":"The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease","volume":"31","author":"Tarrant","year":"2017","journal-title":"Alzheimer Dis Assoc Disord"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724002036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724002036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:10:27Z","timestamp":1737339027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724002036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2274580724002036"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2023.27","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outreach, Screening, and Randomization of APOE \u03b54 Carriers into an Alzheimer's Prevention Trial: A global Perspective from the API Generation Program","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2023.27","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}